Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014806585> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2014806585 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLThe epidermal growth factor receptor (EGFR) regulates several oncogenic signaling pathways including PI3K/AKT/mTOR, MEK/ERK, and STAT. A number of EGFR antagonists have been approved for treatment of late-stage tumors of epithelial origin. Despite these advances, there are several limitations to these therapies, including primary and acquired resistance, prompting the need to combine EGFR antagonists with agents that target pathways downstream of EGFR. CK2 modulates multiple pro-proliferative and pro-survival signals through many of these same signaling pathways, and co-overexpression of EGFR and CK2 has been frequently observed in solid tumors. Here we present the combination of EGFR-targeted agents with CX-4945, a first-in-class selective CK2 inhibitor currently under evaluation in a Phase I clinical trial. CK2 phosphorylates several key proteins at multiple levels within the PI3K/AKT/mTOR signaling pathway including AKT, PTEN, and p70S6K1. CK2 also regulates the Hsp90/Cdc37 machinery, whose clients include EGFR, AKT, and Src. We proposed that top-down inhibition of EGFR, combined with lateral inhibition of the PI3K/ATK/mTOR pathway by CX-4945, would result in an improved cancer therapy compared to EGFR antagonism alone. This hypothesis was tested in vitro and in vivo in A431 squamous cell carcinoma (SCC) and non-small cell lung carcinoma (NSCLC) models of various genetic backgrounds. Signaling pathways and induction of apoptosis were analyzed by western blot and cell proliferation was measured in a 96-hour cell viability assay. The combination of CX-4945 and erlotinib resulted in enhanced reduction in phosphorylation of AKT (T308), AKT (S473), PRAS40 (S246), mTOR (S2481), mTOR (S2448), p70S6K1 (T389), S6 (S235/6), S6 (240/4), and 4E-BP1 (T37/46), and decreased Mcl-1 levels. These effects were accompanied by decreased cell proliferation and synergistic induction of apoptosis. CX-4945 plus erlotinib exhibited enhanced antitumor activity in A431 SCC and NCI-H2170 NSCLC xenograft models; moreover, in the erlotinib-resistant NCI-H1975 NSCLC xenograft model, CX-4945 plus cetuximab resulted in enhanced efficacy. These data suggest that CX-4945 in combination with EGFR-targeted agents may improve clinical outcomes in patients with EGFR and CK2-driven cancers by inhibiting multiple nodes of the EGFR signaling pathway.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2560. doi:10.1158/1538-7445.AM2011-2560" @default.
- W2014806585 created "2016-06-24" @default.
- W2014806585 creator A5012365333 @default.
- W2014806585 creator A5013106114 @default.
- W2014806585 creator A5016891210 @default.
- W2014806585 creator A5018485011 @default.
- W2014806585 creator A5038673041 @default.
- W2014806585 creator A5050105826 @default.
- W2014806585 creator A5050272324 @default.
- W2014806585 creator A5067274113 @default.
- W2014806585 creator A5073648232 @default.
- W2014806585 creator A5074653496 @default.
- W2014806585 date "2011-04-15" @default.
- W2014806585 modified "2023-09-25" @default.
- W2014806585 title "Abstract 2560: The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway" @default.
- W2014806585 doi "https://doi.org/10.1158/1538-7445.am2011-2560" @default.
- W2014806585 hasPublicationYear "2011" @default.
- W2014806585 type Work @default.
- W2014806585 sameAs 2014806585 @default.
- W2014806585 citedByCount "0" @default.
- W2014806585 crossrefType "proceedings-article" @default.
- W2014806585 hasAuthorship W2014806585A5012365333 @default.
- W2014806585 hasAuthorship W2014806585A5013106114 @default.
- W2014806585 hasAuthorship W2014806585A5016891210 @default.
- W2014806585 hasAuthorship W2014806585A5018485011 @default.
- W2014806585 hasAuthorship W2014806585A5038673041 @default.
- W2014806585 hasAuthorship W2014806585A5050105826 @default.
- W2014806585 hasAuthorship W2014806585A5050272324 @default.
- W2014806585 hasAuthorship W2014806585A5067274113 @default.
- W2014806585 hasAuthorship W2014806585A5073648232 @default.
- W2014806585 hasAuthorship W2014806585A5074653496 @default.
- W2014806585 hasConcept C121608353 @default.
- W2014806585 hasConcept C126322002 @default.
- W2014806585 hasConcept C2777609662 @default.
- W2014806585 hasConcept C2779438470 @default.
- W2014806585 hasConcept C502942594 @default.
- W2014806585 hasConcept C55493867 @default.
- W2014806585 hasConcept C57074206 @default.
- W2014806585 hasConcept C62112901 @default.
- W2014806585 hasConcept C62478195 @default.
- W2014806585 hasConcept C71924100 @default.
- W2014806585 hasConcept C75217442 @default.
- W2014806585 hasConcept C86554907 @default.
- W2014806585 hasConcept C86803240 @default.
- W2014806585 hasConcept C95444343 @default.
- W2014806585 hasConceptScore W2014806585C121608353 @default.
- W2014806585 hasConceptScore W2014806585C126322002 @default.
- W2014806585 hasConceptScore W2014806585C2777609662 @default.
- W2014806585 hasConceptScore W2014806585C2779438470 @default.
- W2014806585 hasConceptScore W2014806585C502942594 @default.
- W2014806585 hasConceptScore W2014806585C55493867 @default.
- W2014806585 hasConceptScore W2014806585C57074206 @default.
- W2014806585 hasConceptScore W2014806585C62112901 @default.
- W2014806585 hasConceptScore W2014806585C62478195 @default.
- W2014806585 hasConceptScore W2014806585C71924100 @default.
- W2014806585 hasConceptScore W2014806585C75217442 @default.
- W2014806585 hasConceptScore W2014806585C86554907 @default.
- W2014806585 hasConceptScore W2014806585C86803240 @default.
- W2014806585 hasConceptScore W2014806585C95444343 @default.
- W2014806585 hasLocation W20148065851 @default.
- W2014806585 hasOpenAccess W2014806585 @default.
- W2014806585 hasPrimaryLocation W20148065851 @default.
- W2014806585 hasRelatedWork W1488831821 @default.
- W2014806585 hasRelatedWork W1565370786 @default.
- W2014806585 hasRelatedWork W1593299612 @default.
- W2014806585 hasRelatedWork W1965697171 @default.
- W2014806585 hasRelatedWork W1971718037 @default.
- W2014806585 hasRelatedWork W1974847342 @default.
- W2014806585 hasRelatedWork W2002144745 @default.
- W2014806585 hasRelatedWork W2032151470 @default.
- W2014806585 hasRelatedWork W2054913631 @default.
- W2014806585 hasRelatedWork W2079702205 @default.
- W2014806585 hasRelatedWork W2079848121 @default.
- W2014806585 hasRelatedWork W2083927500 @default.
- W2014806585 hasRelatedWork W2588612263 @default.
- W2014806585 hasRelatedWork W2603142232 @default.
- W2014806585 hasRelatedWork W2887140874 @default.
- W2014806585 hasRelatedWork W2954496070 @default.
- W2014806585 hasRelatedWork W2956072323 @default.
- W2014806585 hasRelatedWork W2991303558 @default.
- W2014806585 hasRelatedWork W3015650006 @default.
- W2014806585 hasRelatedWork W3092244128 @default.
- W2014806585 isParatext "false" @default.
- W2014806585 isRetracted "false" @default.
- W2014806585 magId "2014806585" @default.
- W2014806585 workType "article" @default.